Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CD69 | Q07108 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 6/20 | 0.33 |
| ▸ | VHL | P40337 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8117751 | 0.81 | PPARA (0.41) | PPARAPPARDVHLMAPTKDM4E | |
| SCHEMBL2251477 | 0.77 | NOTUM (0.36) | ALDH1A1 | |
| SCHEMBL5099353 | 0.77 | PPARA (0.38) | PPARA | |
| SCHEMBL13308736 | 0.76 | PPARA (0.48) | PPARAVHLMAPTGAA | |
| SCHEMBL5789049 | 0.76 | ALDH1A1 (0.37) | BACE1MAPTALDH1A1HPGD | |
| SCHEMBL2324543 | 0.76 | RAB9A (0.38) | MAPT | |
| SCHEMBL2251637 | 0.75 | NOTUM (0.34) | — | |
| SCHEMBL25930327 | 0.74 | PPARA (0.48) | PPARAALDH1A1 | |
| SCHEMBL4882325 | 0.74 | CNR2 (0.39) | MAPT | |
| SCHEMBL2254668 | 0.74 | MEN1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| EP-1660087-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
| WO-2005009967-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | FLT3, ABL1, FES | PPARA 4190/4885ELANE 4351/4885CD69 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.